| Literature DB >> 29233042 |
Sunjay Nunley1, Peter Glynn1, Steve Rust2, Jorge Vidaurre1, Dara V F Albert1, Anup D Patel1.
Abstract
To investigate connections between patient demographics, health care utilization, prescription use, and refills for patients using intranasal midazolam, per rectum diazepam, or both. A retrospective cohort contained patients with epilepsy prescribed intranasal midazolam, per rectum diazepam, or both. We analyzed number of emergency department visits, ambulance services, urgent care visits, and unplanned hospitalizations. A total of 5458 patients were identified. Patients on intranasal midazolam had on average 1.53 fewer emergency department visits (95% confidence interval 1.16-1.89, P < .0001), 0.29 fewer uses of ambulance services (95% confidence interval 0.17-0.41, P < .0001), and 0.60 fewer urgent care visits (95% confidence interval 0.36-0.83, P < .0001) compared to patients in the per rectum diazepam group. Patients with commercial insurance were more likely to have intranasal midazolam prescription (odds ratio = 1.73, 95% confidence interval 1.42-2.11, P < .0001). The results substantiate the cost-effective benefits of prescribing intranasal midazolam compared to per rectum diazepam because several aspects of health care utilization were decreased in those using intranasal midazolam.Entities:
Keywords: outcome; pediatric; quality of life; seizures; status epilepticus
Mesh:
Substances:
Year: 2017 PMID: 29233042 DOI: 10.1177/0883073817744696
Source DB: PubMed Journal: J Child Neurol ISSN: 0883-0738 Impact factor: 1.987